Patent ID: 9636337
Date: 2017-05-02
CPC Classifications: A61K,A61P,C07D

Claim:
1. A method of treating a disease or disorder mediated by the mGluR 2 receptor, said method comprising administering to an individual in need thereof an effective amount of a compound of Formula (V): or a stereoisomer thereof, or a pharmaceutically acceptable salt of said compound or said stereoisomer, wherein: ring A is a moiety selected from the group consisting of: phenyl, —(C R -L- is a bond or a divalent moiety selected from the group consisting of: —(C(R —C(O)—, —S(O)—, and —S(O) 2 —; p is 1, 2, or 3; each R R (1) heterocycloalkyl, heterocycloalkenyl, wherein said heterocycloalkyl and said heterocycloalkenyl are monocyclic or multicyclic ring systems comprising from 3 to 10 ring atoms in which 1, 2, or 3 of the atoms of each said ring system is a ring heteroatom independently selected from the group consisting of N, S, S(O), S(O) and wherein each said heterocycloalkyl group and each said heterocycloalkenyl group is unsubstituted or substituted with 1 to 5 groups independently selected from the group consisting of oxo, CN, —OH, halogen, —(C wherein each R (2) heteroaryl, wherein said heteroaryl is a monocyclic or multicyclic ring system comprising from 5 to 10 ring atoms in which from 1 to 4 of the atoms of said ring system is a ring nitrogen atom, and wherein said heteroaryl is unsubstituted or substituted with 1 to 5 groups independently selected from the group consisting of oxo, CN, —OH, halogen, —(C wherein each R with the proviso that R (3) phenyl, wherein said phenyl is unsubstituted or substituted with from 1 to 5 groups independently selected from the group consisting of oxo, CN, —OH, halogen, —(C wherein each R (4) —CH (5) —CH n is 0, 1, 2, or 3; each R R